In addition, Greif et al. proved negative prognostic significance in elderly (> 60 years) cytogenetically normal AML, whereas this could not be confirmed for younger patients [14, 16], suggesting age-dependency of the poor prognostic impact of RUNX1 mutation. This evidence concerns the gene RUNX1 and acute myeloid leukemia.